Goldman Sachs Reiterates Buy Rating on Iovanace Biotherapeutics (IOVA)

H.C. Wainwright Reiterates Buy Rating on Iovanace Biotherapeutics (IOVA)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $20.00 price target on Iovanace Biotherapeutics (NASDAQ: IOVA).

The analyst commented: "In addition to disclosing updated data from C-144-01 and hosting a KOL discussion, Iovance presented poster a detailing its ongoing clinical trial assessing TIL therapy in solid tumors, including NSCLC. Recall, IOV-COM-202 is an open-label Phase 2 study evaluating lifileucel in solid tumors; cohort 3A is... More

Citizens JMP Reiterates Market Perform Rating on Iovanace Biotherapeutics (IOVA)

Citizens JMP analyst Reni J. Benjamin reiterated a Market Perform rating on Iovanace Biotherapeutics (NASDAQ: IOVA).

The analyst commented, We reiterate our Market Perform rating on Iovance Biotherapeutics based on a discounted revenue multiple analysis. During ASCO, Iovance presented five-year outcomes from the C-144-01... More

Iovance Biotherapeutics (IOVA) Announces Publication on Amtagvi

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that the Journal of Clinical Oncology has published the final analysis from the Phase 2 C-144-01 clinical trial evaluating the individualized T cell therapy Amtagvi® (lifileucel) in patients with advanced melanoma. These five-year follow-up results are being simultaneously presented during an oral session today at the 2025 American Society of... More

Citizens JMP: Standard of Care Modifying Regimens at ASCO 2025

Citizens JMP released an industry report discussing the abstract titles from companies in the firms coverage, and outside, to be presented at the 2025 American Society of Clinical Oncology (ASCO) annual meeting.

The analyst commented, Abstract titles for presenting companies were released on April 23. Companies in the Citizens' coverage... More